These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 8456474)

  • 1. Monoclonal antibodies in prophylactic immunosuppression after liver transplantation. A randomized controlled trial comparing OKT3 and anti-IL-2 receptor monoclonal antibody LO-Tact-1.
    Reding R; Vraux H; de Ville de Goyet J; Sokal E; de Hemptinne B; Latinne D; Rahier J; Jamart J; Vincenzotto C; Cormont F
    Transplantation; 1993 Mar; 55(3):534-41. PubMed ID: 8456474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylactic immunosuppression with anti-interleukin-2 receptor monoclonal antibody LO-Tact-1 versus OKT3 in liver allografting. A two-year follow-up study.
    Reding R; Feyaerts A; Vraux H; Latinne D; De La Parra B; Cornet A; Cormont F; Jamart J; Sokal E; de Ville de Goyet J; Lerut J; Bazin H; Otte JB
    Transplantation; 1996 May; 61(9):1406-9. PubMed ID: 8629306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, placebo-controlled trial with anti-interleukin-2 receptor antibody for immunosuppressive induction therapy after liver transplantation.
    Langrehr JM; Glanemann M; Guckelberger O; Klupp J; Neumann U; Machens C; Lohmann R; Knoop M; Lobeck H; Schlag H; Keck H; Settmacher U; Bechstein WO; Neuhaus PJ
    Clin Transplant; 1998 Aug; 12(4):303-12. PubMed ID: 9686324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoprophylaxis with a monoclonal anti-IL-2 receptor antibody in liver transplant patients.
    Nashan B; Schlitt HJ; Schwinzer R; Ringe B; Kuse E; Tusch G; Wonigeit K; Pichlmayr R
    Transplantation; 1996 Feb; 61(4):546-54. PubMed ID: 8610379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylactic use of the IL-2 receptor-specific monoclonal antibody LO-Tact-1 with cyclosporin A and steroids in renal transplantation.
    Hiesse C; Kriaa F; Alard P; Lantz O; Noury J; Bensadoun H; Benoit G; Charpentier B; Fries D; Bazin H
    Transpl Int; 1992; 5 Suppl 1():S444-7. PubMed ID: 14621841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation.
    Clark G; Walsh G; Deshpande P; Koffman G
    Nephrol Dial Transplant; 2002 Jul; 17(7):1304-9. PubMed ID: 12105256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients.
    Calmus Y; Scheele JR; Gonzalez-Pinto I; Jaurrieta EJ; Klar E; Pageaux GP; Scudamore CH; Cuervas-Mons V; Metselaar HJ; Prestele H; Girault D
    Liver Transpl; 2002 Feb; 8(2):123-31. PubMed ID: 11862588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of steroid-resistant and recurrent acute cardiac transplant rejection with a short course of antibody therapy.
    Cantarovich M; Latter DA; Loertscher R
    Clin Transplant; 1997 Aug; 11(4):316-21. PubMed ID: 9267721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infection and rejection of primary hepatic transplant in 93 consecutive patients treated with triple immunosuppressive therapy.
    Ascher NL; Stock PG; Bumgardner GL; Payne WD; Najarian JS
    Surg Gynecol Obstet; 1988 Dec; 167(6):474-84. PubMed ID: 3055368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term results (10 years) of a prospective trial comparing Lo-tact-1 monoclonal antibody and anti-thymocyte globulin induction therapy in kidney transplantation.
    Beaudreuil S; Durrbach A; Noury J; Ducot B; Kriaa F; Bazin H; Charpentier B
    Transpl Int; 2006 Oct; 19(10):814-20. PubMed ID: 16961773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group.
    Nashan B; Moore R; Amlot P; Schmidt AG; Abeywickrama K; Soulillou JP
    Lancet; 1997 Oct; 350(9086):1193-8. PubMed ID: 9652559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective randomized trial of OKT3- versus horse antithymocyte globulin-based immunosuppressive prophylaxis in heart transplantation.
    Costanzo-Nordin MR; O'Sullivan EJ; Johnson MR; Winters GL; Pifarre R; Radvany R; Zucker MJ; Scanlon PJ; Robinson JA
    J Heart Transplant; 1990; 9(3 Pt 2):306-15. PubMed ID: 2113094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. OKT3 induction and steroid-free maintenance immunosuppression for treatment of high-risk heart transplant recipients.
    Prieto M; Lake KD; Pritzker MR; Jorgensen CR; Arom KV; Love KR; Emery RW
    J Heart Lung Transplant; 1991; 10(6):901-11. PubMed ID: 1661608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting factors of long-term results of OKT3 therapy for steroid resistant acute rejection following cadaveric renal transplantation.
    Rostaing L; Chabannier MH; Modesto A; Rouzaud A; Cisterne JM; Tkaczuk J; Durand D
    Am J Nephrol; 1999; 19(6):634-40. PubMed ID: 10592356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Value of a powerful initial immunosuppression after liver transplantation. Prospective study of 60 cases].
    Cherqui D; Duvoux C; Charlotte F; Humeres R; Lauzet JY; Métreau JM; Salvat A; Rotman N; Julien M; Fagniez PL
    Gastroenterol Clin Biol; 1994; 18(2):115-22. PubMed ID: 8013792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized prospective trial of low-dose OKT3 induction therapy to prevent rejection and minimize side effects in recipients of kidney transplants.
    Flechner SM; Goldfarb DA; Fairchild R; Modlin CS; Fisher R; Mastroianni B; Boparai N; O'Malley KJ; Cook DJ; Novick AC
    Transplantation; 2000 Jun; 69(11):2374-81. PubMed ID: 10868643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective randomized trial comparing interleukin-2 receptor antibody versus antithymocyte globulin as part of a quadruple immunosuppressive induction therapy following orthotopic liver transplantation.
    Langrehr JM; Nüssler NC; Neumann U; Guckelberger O; Lohmann R; Radtke A; Jonas S; Klupp J; Steinmüller T; Lobeck H; Meuer S; Schlag H; Lemmens HP; Knoop M; Keck H; Bechstein WO; Neuhaus P
    Transplantation; 1997 Jun; 63(12):1772-81. PubMed ID: 9210503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of the anti-CD25 monoclonal antibody BT563 on clinical and biological rejection after orthotopic liver transplantation.
    Otto G; Hofmann WJ; Gaweco AS; Seelos R; Herfarth C; Meuer S
    Transplant Proc; 1996 Dec; 28(6):3210-1. PubMed ID: 8962244
    [No Abstract]   [Full Text] [Related]  

  • 19. Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage.
    Liu CL; Fan ST; Lo CM; Chan SC; Ng IO; Lai CL; Wong J
    Liver Transpl; 2004 Jun; 10(6):728-33. PubMed ID: 15162466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized prospective trial of OKT3 for early prophylaxis of rejection after liver transplantation.
    Millis JM; McDiarmid SV; Hiatt JR; Brems JJ; Colonna JO; Klein AS; Ashizawa T; Hart J; Lewin K; Goldstein LI
    Transplantation; 1989 Jan; 47(1):82-8. PubMed ID: 2521409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.